Should we Cryopreserve Allogenic Hematopoietic Stem Cell Grafts?

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL In vivo Pub Date : 2025-03-01 DOI:10.21873/invivo.13890

Ewa Bembnista, Patrycja Stawicka, Paula Matuszak, Anna Łojko-Dankowska, Dominik Dytfeld, Magdalena Matuszak, Anna Wache, Katarzyna Kaźmierska, Ewa Majewska, Krzysztof Lewandowski, Lidia Gil

{"title":"Should we Cryopreserve Allogenic Hematopoietic Stem Cell Grafts?","authors":"Ewa Bembnista, Patrycja Stawicka, Paula Matuszak, Anna Łojko-Dankowska, Dominik Dytfeld, Magdalena Matuszak, Anna Wache, Katarzyna Kaźmierska, Ewa Majewska, Krzysztof Lewandowski, Lidia Gil","doi":"10.21873/invivo.13890","DOIUrl":null,"url":null,"abstract":"Background/aim: Cryopreservation of allogeneic hematopoietic cells can be an necessary step in the preparation of a graft for transplantation. The purpose of this study was to evaluate the safety of cryopreservation of allogeneic hematopoietic cells and the clinical outcomes of patients who received a cryopreserved transplant.Patients and methods: The study included data from a comparative analysis conducted on a group of 100 patients diagnosed with acute myeloid leukemia who received cryopreserved (50 patients) and fresh (50 patients) transplants. Both quantitative and qualitative parameters of the grafts were evaluated, as well as the patients' hematopoietic recovery.Results: Statistical analysis of the time to engraftment of neutrophils, nucleated cells, and platelets showed no differences between the group of patients who received cryopreserved transplants and those who received fresh transplants. A higher count of CD34+ cells in the graft significantly reduced the time required for patients to reach their reference values of neutrophils, nuclear cells, and platelets (p<0.05).Conclusion: Cryopreservation of allogenic transplants should be reserved as an option when fresh grafts are not feasible for various reasons.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"870-876"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13890","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Cryopreservation of allogeneic hematopoietic cells can be an necessary step in the preparation of a graft for transplantation. The purpose of this study was to evaluate the safety of cryopreservation of allogeneic hematopoietic cells and the clinical outcomes of patients who received a cryopreserved transplant.

Patients and methods: The study included data from a comparative analysis conducted on a group of 100 patients diagnosed with acute myeloid leukemia who received cryopreserved (50 patients) and fresh (50 patients) transplants. Both quantitative and qualitative parameters of the grafts were evaluated, as well as the patients' hematopoietic recovery.

Results: Statistical analysis of the time to engraftment of neutrophils, nucleated cells, and platelets showed no differences between the group of patients who received cryopreserved transplants and those who received fresh transplants. A higher count of CD34+ cells in the graft significantly reduced the time required for patients to reach their reference values of neutrophils, nuclear cells, and platelets (p<0.05).

Conclusion: Cryopreservation of allogenic transplants should be reserved as an option when fresh grafts are not feasible for various reasons.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.